In trading on Tuesday, shares of argenx SE (ARGX) crossed above their 200‑day moving average of $744.48, changing hands as high as $748.30 per share. argenx SE shares are currently trading up about 0.1% on the day. Technical analysts often view sustained moves above a long‑term moving average as a potential confirmation of improving price momentum.

The chart below shows the one‑year performance of ARGX shares versus their 200‑day moving average:

Looking at the chart above, ARGX—s low point in its 52‑week range is $510.055 per share, with $934.6199 as the 52‑week high point — that compares with a last trade of $742.17.

argenx SE is a Netherlands‑based immunology company focused on developing antibody‑based therapies for severe autoimmune diseases and certain cancers. Its lead commercial product, efgartigimod, is approved in multiple markets for generalized myasthenia gravis and is being evaluated in additional autoimmune indications. As a result, ARGX shares can be sensitive to clinical trial readouts, regulatory decisions, and partnership activity, alongside broader moves in the biotechnology sector.

From a technical perspective, some market participants look for confirmation that a break above a 200‑day moving average is sustained over several trading sessions and accompanied by stronger trading volume before interpreting the move as evidence of a durable change in trend. Others may compare ARGX—s current valuation and pipeline milestones with those of peer biotechnology companies to assess whether the recent price action is supported by company fundamentals.